Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BCG033

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Biocytogen

Drug class:

TROP-2-targeted antibody-drug conjugate, PTK7-targeted antibody-drug conjugate

Related drugs:

PTK7 expression + TROP2 expression	Triple Negative Breast Cancer	PTK7 expression + TROP2 expression	Triple Negative Breast Cancer	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D
PTK7 expression + TROP2 expression	Solid Tumor	PTK7 expression + TROP2 expression	Solid Tumor	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D
PTK7 expression	Triple Negative Breast Cancer	PTK7 expression	Triple Negative Breast Cancer	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D	BCG033 Sensitive: D – Preclinical BCG033 Sensitive : D